Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 4/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14192045 | 0.88 | PTGDR2 (0.41) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5107317 | 0.87 | SMN1; SMN2 (0.50) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL583126 | 0.84 | MEN1 (0.51) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL583125 | 0.84 | MEN1 (0.51) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL582663 | 0.83 | MEN1 (0.52) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL582664 | 0.83 | MEN1 (0.52) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5104107 | 0.81 | MEN1 (0.49) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL23640061 | 0.75 | MEN1 (0.58) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL582537 | 0.75 | MEN1 (0.58) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL582538 | 0.75 | MEN1 (0.58) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1807076-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006060108-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1807076-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006060108-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | MEN1 2668/4885KMT2A 1791/4885POLB 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.